Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …

Breast carcinomas can be stratified into different entities based on clinical behavior,
histologic features, and/or by biological properties. A classification of breast cancer should …

Distant metastasis accounts for the vast majority of deaths in patients with cancer. Breast
cancer exhibits a distinct metastatic pattern commonly involving bone, liver, lung, and brain …

Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen
receptor, progesterone receptor and ERBB2 gene amplification, represent approximately …

There is now strong evidence that mutation not only abrogates p53 tumor-suppressive
functions, but in some instances can also endow mutant proteins with novel activities. Such …

Somatic mutations in the TP53 gene are one of the most frequent alterations in human
cancers, and germline mutations are the underlying cause of Li-Fraumeni syndrome, which …

Summary p53 is a frequent target for mutation in human tumors, and mutant p53 proteins
can actively contribute to tumorigenesis. We employed a three-dimensional culture model in …

Objective The aim of this article is to discuss mutant p53 as a possible therapeutic target and
biomarker for breast cancer. Results TP53 (p53) is the most frequently mutated gene in …

High-throughput biological data, whether generated as sequencing, transcriptional
microarrays, proteomic, or other means, continues to require analytic methods that address …

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive
functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies …